Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
MDR-TB most commonly develops in the course of TB treatment, [5] and is most commonly due to doctors giving inappropriate treatment, or patients missing doses or failing to complete their treatment. Because MDR tuberculosis is an airborne pathogen, persons with active, pulmonary tuberculosis caused by a multidrug-resistant strain can transmit ...
It is a fixed dose combination of ethambutol, isoniazid, pyrazinamide, and rifampicin. [1] It is used either alone or with other antituberculosis medication. [1] It is taken by mouth. [1] Side effects are those of the underlying medications. [1] Pyridoxine may be used to decrease the risk of numbness. [2]
Latent TB is treated with either isoniazid or rifampin alone, or a combination of isoniazid with either rifampicin or rifapentine. [140] [141] [142] The treatment takes three to nine months depending on the medications used. [75] [140] [143] [142] People with latent infections are treated to prevent them from progressing to active TB disease ...
Rifampicin is used for the treatment of tuberculosis in combination with other antibiotics, such as pyrazinamide, isoniazid, and ethambutol. [10] For the treatment of tuberculosis, it is administered daily for at least six months. [11] Combination therapy is used to prevent the development of resistance and to shorten the length of treatment. [12]
Combination therapy or polytherapy is therapy that uses more than one medication or modality. Typically, the term refers to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical (although it can also involve non-medical therapy, such as the combination of medications and talk therapy to treat depression).
(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge ...
The drug proved better than streptomycin, which had nerve toxicity and to which TB could easily develop resistance. In 1948, researchers at Britain's Medical Research Council demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone, and established the principle of combination therapy for tuberculosis. [8 ...